HRP20150310T1 - Cjepivo protiv rotavirusa koje inducira heterotipnu ukriženu zaštitu - Google Patents
Cjepivo protiv rotavirusa koje inducira heterotipnu ukriženu zaštitu Download PDFInfo
- Publication number
- HRP20150310T1 HRP20150310T1 HRP20150310TT HRP20150310T HRP20150310T1 HR P20150310 T1 HRP20150310 T1 HR P20150310T1 HR P20150310T T HRP20150310T T HR P20150310TT HR P20150310 T HRP20150310 T HR P20150310T HR P20150310 T1 HRP20150310 T1 HR P20150310T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- rotavirus
- preparation
- strain
- adenine
- Prior art date
Links
- 229940124859 Rotavirus vaccine Drugs 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 241000702670 Rotavirus Species 0.000 claims 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 12
- 229930024421 Adenine Natural products 0.000 claims 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 7
- 229960000643 adenine Drugs 0.000 claims 7
- 108091081024 Start codon Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 229940113082 thymine Drugs 0.000 claims 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 206010017913 Gastroenteritis rotavirus Diseases 0.000 claims 1
- 206010067470 Rotavirus infection Diseases 0.000 claims 1
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 230000001458 anti-acid effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (17)
1. Upotreba oslabljenog soja rotavirusa tipa G1P[8], naznačena time što je oslabljeni soj namijenjen proizvodnji pripravka namijenjenog pružanju zaštite protiv infekcije rotavirusom uzrokovane sojem rotavirusa tipa G2P[4].
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što pripravak sadrži rotavirus čiji gen VP4 ima, u nukleotidnom slijedu, najmanje jedno od sljedećeg: adeninsku bazi (A) na položaju 788, adeninsku bazu (A) na položaju 802 i timinsku bazu (T) na položaju 501 iza početnog kodona.
3. Upotreba u skladu s patentnim zahtjevom 2, naznačena time što gen VP4 ima nukleotidni slijed koji ima adeninsku bazu (A) na položajima 788 i 802 i timinsku bazu (T) na položaju 501 iza početnog kodona.
4. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačena time što pripravak sadrži rotavirus čiji gen VP7 ima, u nukleotidnom slijedu, najmanje jedno od sljedećeg: timin (T) na položaju 605, adenin (A) na položaju 897 i gvanin (G) na položaju 897 iza početnog kodona.
5. Upotreba u skladu s patentnim zahtjevom 4, naznačena time što gen VP7 ima nukleotidni slijed koji ima timin (T) na položaju 605 i adenin (A) ili gvanin (G) na položaju 897 iza početnog kodona.
6. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što pripravak sadrži rotavirus čiji gen VP4 ima, u nukleotidnom slijedu, adenin (A) na položajima 788 i 802 i timin (T) na položaju 501 iza početnog kodona; te čiji gen VP7 ima, u nukleotidnom slijedu, timin (T) na položaju 605 i adenin (A) na položaju 897 iza početnog kodona.
7. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što pripravak pruža dodatnu zaštitu protiv najmanje jednog od ne-G1 serotipova, koje se bira iz skupine koju čine: G3, G4 i G9.
8. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što pripravak sadrži oslabljeni soj rotavirusa tipa G1P[8] pruža zaštitu protiv teškog rotavirusnog gastroenteritisa s rezultatom jednakim ili većim od 11 na Vesikarijevoj skali, uzrokovanog infekcijomom soja rotavirusa tipa G2P[4].
9. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što pripravak sadrži oslabljeni soj rotavirusa tipa G1P[8] štiti najmanje 40%, u populaciji cijepljenih osoba, protiv proljeva uzrokovanog sojem rotavirusa koji je tipa G2P[4].
10. Upotreba u skladu s patentnim zahtjevom 9, naznačena time što pripravak štiti najmanje 50%.
11. Upotreba u skladu s patentnim zahtjevom 9, naznačena time što pripravak štiti između 40% i 80%.
12. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što pripravak štiti između 50% i 70%.
13. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što pripravak štiti između 40% i 75% u populaciji osoba cijepljenih protiv teškog gastroenteritisa koje imaju rezultat jednak ili veći od 11 na Vesikarijevoj skali uzrokovan infekcijom serotipom G2P[4] rotavirusa.
14. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačena time što je soj rotavirusa u navedenom pripravku ECACC depozit 99081301, ili se može dobiti ili načiniti iz ECACC depozita 99081301.
15. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačena time što se pripravak primijenjuje u dvodoznom režimu.
16. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 15, naznačena time što se oslabljeni soj rotavirusa formulira s pogodnim farmaceutskim nosačem ili s antacidnim puferom ili obojim.
17. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačena time što je pripravak namijenjen pružanju zaštite kod ljudskog subjekta.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0516944A GB0516944D0 (en) | 2005-08-17 | 2005-08-17 | Vaccine |
| GB0521164A GB0521164D0 (en) | 2005-10-18 | 2005-10-18 | Vaccine |
| GB0608962A GB0608962D0 (en) | 2006-05-05 | 2006-05-05 | Vaccine |
| EP10159949.6A EP2233153B1 (en) | 2005-08-17 | 2006-08-15 | Rotavirus vaccine inducing heterotypic cross protection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150310T1 true HRP20150310T1 (hr) | 2015-06-19 |
Family
ID=37757924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150310TT HRP20150310T1 (hr) | 2005-08-17 | 2015-03-18 | Cjepivo protiv rotavirusa koje inducira heterotipnu ukriženu zaštitu |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090028828A1 (hr) |
| EP (2) | EP2233153B1 (hr) |
| JP (1) | JP5519934B2 (hr) |
| KR (1) | KR20080036648A (hr) |
| AR (1) | AR054916A1 (hr) |
| AU (1) | AU2006281566B2 (hr) |
| BR (1) | BRPI0615203A2 (hr) |
| CA (1) | CA2619751C (hr) |
| CR (1) | CR9759A (hr) |
| CY (1) | CY1116135T1 (hr) |
| DK (1) | DK2233153T3 (hr) |
| EA (1) | EA014328B1 (hr) |
| ES (1) | ES2534637T3 (hr) |
| HR (1) | HRP20150310T1 (hr) |
| IL (1) | IL189289A0 (hr) |
| MA (1) | MA29700B1 (hr) |
| MX (1) | MX2008002270A (hr) |
| NO (1) | NO20080754L (hr) |
| PE (1) | PE20070235A1 (hr) |
| PL (1) | PL2233153T3 (hr) |
| PT (1) | PT2233153E (hr) |
| SG (1) | SG163571A1 (hr) |
| SI (1) | SI2233153T1 (hr) |
| TW (1) | TW200740457A (hr) |
| WO (1) | WO2007020078A2 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0107510D0 (en) | 2001-03-26 | 2001-05-16 | Univ Bristol | New elongase gene and a process for the production of -9-polyunsaturated fatty acids |
| US8241886B2 (en) | 2007-09-25 | 2012-08-14 | Aridis Pharmaceuticals | Formulations for preservation of rotavirus |
| US9311112B2 (en) * | 2009-03-16 | 2016-04-12 | Apple Inc. | Event recognition |
| US20140242113A1 (en) * | 2011-04-28 | 2014-08-28 | Leonard P. Ruiz, JR. | Liquid vaccine preparations |
| CN110227152A (zh) * | 2012-04-23 | 2019-09-13 | 巴拉特生物技术国际有限公司 | 轮状病毒疫苗组合物及其制备方法 |
| CN108431214B (zh) | 2015-10-05 | 2022-03-01 | 美国政府(由卫生和人类服务部的部长所代表) | 人轮状病毒g9p[6]毒株和作为疫苗的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9060391A (en) * | 1990-11-16 | 1992-06-11 | James N. Gamble Institute Of Medical Research | Human rotaviruses, vaccines and methods |
| ES2260046T3 (es) * | 1999-08-17 | 2006-11-01 | Glaxosmithkline Biologicals S.A. | Procedimiento para separar variantes rotavirus y vacuna de rotavirus vivos atenuados. |
| KR20060126917A (ko) * | 2003-09-02 | 2006-12-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
-
2006
- 2006-08-15 PE PE2006000993A patent/PE20070235A1/es not_active Application Discontinuation
- 2006-08-15 EP EP10159949.6A patent/EP2233153B1/en active Active
- 2006-08-15 DK DK10159949T patent/DK2233153T3/da active
- 2006-08-15 PT PT101599496T patent/PT2233153E/pt unknown
- 2006-08-15 CA CA2619751A patent/CA2619751C/en active Active
- 2006-08-15 SG SG201004843-7A patent/SG163571A1/en unknown
- 2006-08-15 ES ES10159949.6T patent/ES2534637T3/es active Active
- 2006-08-15 SI SI200631912T patent/SI2233153T1/sl unknown
- 2006-08-15 AR ARP060103557A patent/AR054916A1/es not_active Application Discontinuation
- 2006-08-15 BR BRPI0615203-1A patent/BRPI0615203A2/pt not_active Application Discontinuation
- 2006-08-15 EA EA200800320A patent/EA014328B1/ru not_active IP Right Cessation
- 2006-08-15 PL PL10159949T patent/PL2233153T3/pl unknown
- 2006-08-15 KR KR1020087006496A patent/KR20080036648A/ko not_active Application Discontinuation
- 2006-08-15 TW TW095129956A patent/TW200740457A/zh unknown
- 2006-08-15 MX MX2008002270A patent/MX2008002270A/es unknown
- 2006-08-15 EP EP06776899A patent/EP1915173A2/en not_active Ceased
- 2006-08-15 AU AU2006281566A patent/AU2006281566B2/en not_active Ceased
- 2006-08-15 US US12/063,602 patent/US20090028828A1/en not_active Abandoned
- 2006-08-15 JP JP2008526443A patent/JP5519934B2/ja active Active
- 2006-08-15 WO PCT/EP2006/008094 patent/WO2007020078A2/en active Application Filing
-
2008
- 2008-02-05 IL IL189289A patent/IL189289A0/en unknown
- 2008-02-12 NO NO20080754A patent/NO20080754L/no not_active Application Discontinuation
- 2008-02-13 MA MA30653A patent/MA29700B1/fr unknown
- 2008-02-22 CR CR9759A patent/CR9759A/es not_active Application Discontinuation
-
2015
- 2015-03-18 HR HRP20150310TT patent/HRP20150310T1/hr unknown
- 2015-03-23 CY CY20151100289T patent/CY1116135T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006281566A1 (en) | 2007-02-22 |
| TW200740457A (en) | 2007-11-01 |
| EA200800320A1 (ru) | 2008-10-30 |
| PL2233153T3 (pl) | 2015-06-30 |
| MA29700B1 (fr) | 2008-08-01 |
| EA014328B1 (ru) | 2010-10-29 |
| PE20070235A1 (es) | 2007-04-04 |
| SI2233153T1 (sl) | 2015-05-29 |
| CR9759A (es) | 2008-05-05 |
| CA2619751A1 (en) | 2007-02-22 |
| WO2007020078A2 (en) | 2007-02-22 |
| NO20080754L (no) | 2008-05-15 |
| MX2008002270A (es) | 2008-03-27 |
| PT2233153E (pt) | 2015-04-20 |
| JP5519934B2 (ja) | 2014-06-11 |
| BRPI0615203A2 (pt) | 2011-05-10 |
| US20090028828A1 (en) | 2009-01-29 |
| JP2009504701A (ja) | 2009-02-05 |
| AR054916A1 (es) | 2007-07-25 |
| SG163571A1 (en) | 2010-08-30 |
| KR20080036648A (ko) | 2008-04-28 |
| ES2534637T3 (es) | 2015-04-27 |
| DK2233153T3 (da) | 2015-04-27 |
| CY1116135T1 (el) | 2017-02-08 |
| EP2233153B1 (en) | 2015-01-21 |
| EP1915173A2 (en) | 2008-04-30 |
| IL189289A0 (en) | 2008-06-05 |
| EP2233153A1 (en) | 2010-09-29 |
| WO2007020078A3 (en) | 2007-05-24 |
| CA2619751C (en) | 2016-07-05 |
| AU2006281566B2 (en) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150310T1 (hr) | Cjepivo protiv rotavirusa koje inducira heterotipnu ukriženu zaštitu | |
| HRP20160299T1 (hr) | Cjepivo protiv rotavirusa | |
| Sun et al. | Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates | |
| Matsuno et al. | A candidate for a new serotype of human rotavirus | |
| Edelman et al. | Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine | |
| Ridpath et al. | Phylogenetic, antigenic and clinical characterization of type 2 BVDV from North America | |
| Kapikian et al. | Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a Jennerian approach to vaccination | |
| Heinz et al. | Tick-borne encephalitis and the impact of vaccination | |
| Clements-Mann et al. | Safety and immunogenicity of live attenuated quadrivalent human–bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants | |
| Rennels et al. | An efficacy trial of the rhesus rotavirus vaccine in Maryland | |
| Chernokhaeva et al. | Protective immunity spectrum induced by immunization with a vaccine from the TBEV strain Sofjin | |
| WO1998000165A1 (en) | Porcine reproductive and respiratory syndrome vaccine | |
| Pang et al. | Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis | |
| Lai et al. | Evaluation of molecular strategies to develop a live dengue vaccine | |
| Glass et al. | First rotavirus vaccine licensed: is there really a need? | |
| Plotkin | Vaccination in the 21st century | |
| Beer et al. | A new inactivated BVDV genotype I and II vaccine: an immunisation and challenge study with BVDV genotype I | |
| Tešović | Childhood vaccinations in Croatia | |
| DK0701612T3 (da) | Immunogent præparat af OspC-antigenvacciner til forebyggelse og behandling af Lyme sygdom og rekombinantmetode til fremsti | |
| MacLachlan et al. | Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness | |
| Advisory Committee on Immunization Practices | Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices. | |
| ES2637629T3 (es) | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo | |
| JP2007516215A5 (hr) | ||
| Galler et al. | Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys | |
| Bart et al. | Vaccine-preventable disease and immunization in the developing world |